Drug
Sublingual film containing dexmedetomidine (BXCL501)
Sublingual film containing dexmedetomidine (BXCL501) is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Phase Distribution
Ph phase_4
1
33%
Ph phase_3
2
67%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 32 (66.7%)
Phase 41 (33.3%)
Trials by Status
withdrawn133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
withdrawnphase_4
Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department
NCT05974527
completedphase_3
Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
NCT04276883
completedphase_3
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
NCT04268303
Clinical Trials (3)
Showing 3 of 3 trials
NCT05974527Phase 4
Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department
NCT04276883Phase 3
Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
NCT04268303Phase 3
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3